

Lung Cancer

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Trial Status
Completed

Trial Runs In
6 Countries

Trial Identifier
NCT03092739 MO29978

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03092739 MO29978
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No